July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Comparison of the effects of intravitreal aflibercept, bevacizumab and ranibizumab on retinal function and vasculature after oxygen-induced retinopathy
Author Affiliations & Notes
  • wai ching Lam
    Ophthalmology and Vision Sciences, University of Hong Kong, Hong Kong, Hong Kong
  • Jessica Tsang
    Ophthalmology and Vision Sciences, University of Hong Kong, Hong Kong, Hong Kong
  • Amy CY Lo
    Ophthalmology and Vision Sciences, University of Hong Kong, Hong Kong, Hong Kong
  • Footnotes
    Commercial Relationships   wai ching Lam, Alcon (F), Bayer (C), Novartis (C); Jessica Tsang, None; Amy Lo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5407. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      wai ching Lam, Jessica Tsang, Amy CY Lo; Comparison of the effects of intravitreal aflibercept, bevacizumab and ranibizumab on retinal function and vasculature after oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5407.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Vascular endothelial growth factor (VEGF) level plays a critical role on progression of retinopathy of prematurity (ROP). Anti-VEGF therapies including aflibercept, bevacizumab or ranibizumab have been used as treatment for Advance ROP. Although the efficacy and effectiveness of these drugs on ROP are well recognized, its effect on the retinal function is largely unknown. Therefore, the effects of these 3 drugs on the retinal function and vasculature in ROP were investigated using the mouse oxygen-induced retinopathy (OIR) model

Methods : 75% oxygen was provided to C57Bl/6J mice at postnatal day (P) 7 to P12, which were then returned to room air (RA). Intravitreal injection of PBS (control), aflibercept (3.33mg/kg), bevacizumab (5.18mg/kg), or ranibizumab (2.06mg/kg) was performed on one eye on P14. On P21, retinal function was analyzed by scotopic electroretinogram (ERG) and retinal tissue was collected for retinal vasculature visualization using isolectin (GS-IB4) immunohistochemical staining .

Results : Three anti-VEGF drugs showed similar effects on the retinal function after OIR. There was increase of a-wave and b-wave amplitudes on P21 in the ipsilateral eyes but none in the contralateral eyes. Similar implicit times of a-wave and longer implicit time in b-wave was observed in ipsilateral eyes receiving the drugs. Meanwhile, there were longer implicit times of both a-wave and b-wave in the contralateral eyes. Although these 3 drugs showed similar effects on retinal function after OIR, a slight difference was noted in the retinal vasculature. Smaller central avascular zone was observed in the aflibercept-treated eyes. Moreover, eyes receiving the 3 drugs showed a reduction of neovascular area, with the largest decrease in the ranibizumab-treated eyes

Conclusions : Aflibercept, bevacizumab and ranibizumab displayed similar effects with small difference on retinal function and retinal vascular development in the mouse OIR model, suggesting small difference may exist between these 3 types of anti-VEGF for ROP treatment. Our results provided evidence to support the short-term beneficial effects of these 3 anti-VEGF drugs.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×